William D Travis

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. doi Sarcomatoid neoplasms of the lung and pleura
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021
    Arch Pathol Lab Med 134:1645-58. 2010
  2. pmc Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence
    Kei Suzuki
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 31:490-8. 2013
  3. doi Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Arch Pathol Lab Med 137:668-84. 2013
  4. ncbi Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease
    Kyuichi Kadota
    Department of Surgery, Division of Thoracic Service Department of Pathology Department of Epidemiology and Biostatistics Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY Department of Diagnostic Pathology, Faculty of Medicine, Kagawa University, Kagawa Department of Laboratory Medicine, Shinshu University Hospital, Matsumoto Department of Diagnostic Pathology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
    Am J Surg Pathol 38:448-60. 2014
  5. pmc Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2cm or smaller
    Jun ichi Nitadori
    Division of Thoracic Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Tokyo, Japan JN
    J Natl Cancer Inst 105:1212-20. 2013
  6. doi Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab
    Matthew D Hellmann
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical School, 300 East 66th Street, New York, NY 10065, USA
    Cancer Chemother Pharmacol 72:453-61. 2013
  7. pmc Thyroid transcription factor-1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage I lung adenocarcinoma
    Kyuichi Kadota
    Division of Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 119:931-8. 2013
  8. doi A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma
    Kyuichi Kadota
    Division of Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mod Pathol 25:1117-27. 2012
  9. pmc FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma
    Kyuichi Kadota
    Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 19:3598-605. 2012
  10. pmc High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology
    Kyuichi Kadota
    Division of Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Thorac Oncol 7:1192-7. 2012

Detail Information

Publications44

  1. doi Sarcomatoid neoplasms of the lung and pleura
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021
    Arch Pathol Lab Med 134:1645-58. 2010
    ....
  2. pmc Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence
    Kei Suzuki
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 31:490-8. 2013
    ..Our aim was to investigate the prognostic significance of the immune microenvironment in patients with stage I lung adenocarcinoma (ADC)...
  3. doi Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Arch Pathol Lab Med 137:668-84. 2013
    ....
  4. ncbi Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease
    Kyuichi Kadota
    Department of Surgery, Division of Thoracic Service Department of Pathology Department of Epidemiology and Biostatistics Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY Department of Diagnostic Pathology, Faculty of Medicine, Kagawa University, Kagawa Department of Laboratory Medicine, Shinshu University Hospital, Matsumoto Department of Diagnostic Pathology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
    Am J Surg Pathol 38:448-60. 2014
    ..5 cm; n=2), 20% to 30% micropapillary component (n=2), and lymphatic or vascular invasion (n=2). It therefore may be possible to identify lepidic predominant adenocarcinomas that carry a low or high risk for recurrence. ..
  5. pmc Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2cm or smaller
    Jun ichi Nitadori
    Division of Thoracic Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Tokyo, Japan JN
    J Natl Cancer Inst 105:1212-20. 2013
    ....
  6. doi Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab
    Matthew D Hellmann
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical School, 300 East 66th Street, New York, NY 10065, USA
    Cancer Chemother Pharmacol 72:453-61. 2013
    ..The risk of hemoptysis may be eliminated in patients with resected SQCLCs. We evaluated the safety of adjuvant bevacizumab in patients with resected SQCLCs and other lung cancers at high risk of hemoptysis...
  7. pmc Thyroid transcription factor-1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage I lung adenocarcinoma
    Kyuichi Kadota
    Division of Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 119:931-8. 2013
    ....
  8. doi A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma
    Kyuichi Kadota
    Division of Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mod Pathol 25:1117-27. 2012
    ..005) after adjusting for clinical factors. We proposed this combined architectural/mitotic grade for lung adenocarcinoma as a practical method that can be applied in routine practice...
  9. pmc FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma
    Kyuichi Kadota
    Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 19:3598-605. 2012
    ....
  10. pmc High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology
    Kyuichi Kadota
    Division of Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Thorac Oncol 7:1192-7. 2012
    ..We sought to investigate whether preoperative maximum standardized uptake value (SUVmax) on F-fluorodeoxyglucose (FDG) positron emission tomography (PET) correlates with histologic subtype in MPM...
  11. pmc A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma
    Kyuichi Kadota
    Division of Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mod Pathol 25:260-71. 2012
    ..Nuclear grading in epithelioid mesothelioma provides a simple, practical, and cost-effective prognostic tool that better stratifies clinical outcome and time to recurrence than currently available clinicopathologic factors...
  12. doi Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases
    Nicolas Girard
    Pao Lab, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Surg Pathol 33:1752-64. 2009
    ..Given its high correlation with molecular characterization of such tumors, it may provide a much cheaper and faster method to address this problem...
  13. pmc Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations
    Natasha Rekhtman
    Department of Pathology, Thoracic Oncology Service, Department of Medicine, and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, NY 10065, USA
    Clin Cancer Res 18:1167-76. 2012
    ....
  14. doi Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens
    Carlie S Sigel
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York 10065, USA
    J Thorac Oncol 6:1849-56. 2011
    ..The relative feasibility and accuracy of NSCLC subtyping by small biopsy versus cytology is not well established, particularly in current practice where immunohistochemistry (IHC) is becoming routinely used to aid in this distinction...
  15. doi Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases
    Akihiko Yoshizawa
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Mod Pathol 24:653-64. 2011
    ..The slightly stronger association with survival for invasive size versus gross size raises the need for further studies to determine whether this adjustment in measuring tumor size could impact TNM staging for small adenocarcinomas...
  16. pmc Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma
    Natasha Rekhtman
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Mod Pathol 26:511-22. 2013
    ..These findings have practical implications for diagnosis, predictive molecular testing and therapy selection...
  17. doi Predicting pulmonary adenocarcinoma outcome based on a cytology grading system
    Carlie S Sigel
    1Memorial Sloan Kettering Cancer Center, Department of Pathology, New York, New York, USA
    Cancer Cytopathol 120:35-43. 2012
    ..Therefore, we evaluated cytomorphologic features of previously histologically graded AD to identify features of potential prognostic significance...
  18. doi Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients
    Kei Suzuki
    Division of Thoracic Surgery, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Cancer Immunol Immunother 60:1721-8. 2011
    ....
  19. ncbi Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers
    Jamie E Chaft
    Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
    J Thorac Oncol 8:1084-90. 2013
    ..Bevacizumab improves survival in patients with advanced non-small-cell lung cancer (NSCLC). This phase II clinical trial assessed the effects of the addition of bevacizumab to neoadjuvant chemotherapy in resectable nonsquamous NSCLC...
  20. doi Diagnosis of lung adenocarcinoma in resected specimens: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Arch Pathol Lab Med 137:685-705. 2013
    ..It is possible that this classification may impact the next revision of the TNM staging classification, with adjustment of the size T factor according to only the invasive component pathologically in adenocarcinomas with lepidic areas...
  21. doi Neoadjuvant and adjuvant chemotherapy in resected pulmonary large cell neuroendocrine carcinomas: a single institution experience
    Inderpal S Sarkaria
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Thorac Surg 92:1180-6; discussion 1186-7. 2011
    ..Pulmonary large cell neuroendocrine carcinomas (LCNEC) are aggressive neoplasms with poor prognosis. The role of neoadjuvant and adjuvant therapies in these tumors remains uncertain...
  22. doi Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint
    Matthew D Hellmann
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet Oncol 15:e42-50. 2014
    ..Additional prospective studies are needed to confirm the validity and reproducibility of major pathological response within individual histological and molecular subgroups and with new drugs. ..
  23. doi New pathologic classification of lung cancer: relevance for clinical practice and clinical trials
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 31:992-1001. 2013
    ....
  24. doi Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens
    Natasha Rekhtman
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mod Pathol 24:1348-59. 2011
    ..This simple algorithm achieves excellent accuracy in small specimens while conserving the tissue for potential predictive marker testing, which is now an essential consideration in advanced lung cancer specimens...
  25. doi International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Am Thorac Soc 8:381-5. 2011
    ..The American Thoracic Society is a cosponsor of a newly published lung adenocarcinoma classification...
  26. ncbi A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors
    Gabriel Sica
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Surg Pathol 34:1155-62. 2010
    ..65 (95% confidence interval 0.57-0.73). Therefore, this scoring system provides valuable information in discriminating patients with different risk of disease-recurrence in a highly homogeneous population of patients with stage I cancer...
  27. ncbi Prognostic immune markers in non-small cell lung cancer
    Kei Suzuki
    Division of Thoracic Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 17:5247-56. 2011
    ..This first comprehensive review of prognostic immune markers provides a foundation for further investigating immune responses in NSCLC...
  28. doi Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing
    Natasha Rekhtman
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York 10065, USA
    J Thorac Oncol 6:451-8. 2011
    ..The aim of this study was to comprehensively review the performance of cytologic specimens for the above two goals in a high-volume clinical practice...
  29. doi Primary lung adenocarcinomas in children and adolescents treated for pediatric malignancies
    Mark L Kayton
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Thorac Oncol 5:1764-71. 2010
    ..Herein, we present clinical, histopathologic, and molecular data on eight such cases...
  30. ncbi The cribriform pattern identifies a subset of acinar predominant tumors with poor prognosis in patients with stage I lung adenocarcinoma: a conceptual proposal to classify cribriform predominant tumors as a distinct histologic subtype
    Kyuichi Kadota
    1 Division of Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA 2 Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA 3 Department of Diagnostic Pathology, Faculty of Medicine, Kagawa University, Kagawa, Japan
    Mod Pathol 27:690-700. 2014
    ....
  31. pmc Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma
    Stefan S Kachala
    Authors Affiliations Division of Thoracic Surgery Center for Cell Engineering Departments of Pathology, Epidemiology and Biostatistics, and Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
    Clin Cancer Res 20:1020-8. 2014
    ..In an effort to identify molecular markers of tumor aggressiveness and therapeutic targets in lung adenocarcinoma (ADC), we investigated the expression of mesothelin (MSLN) in lung ADC, as well as its biologic and clinical relevance...
  32. doi The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Thorac Oncol 3:1213-23. 2008
    ....
  33. pmc Clinical outcomes with perioperative chemotherapy in sarcomatoid carcinomas of the lung
    Jamie E Chaft
    Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York 10065, USA
    J Thorac Oncol 7:1400-5. 2012
    ..We sought to determine the effect of perioperative chemotherapy in patients with completely resected sarcomatoid carcinomas of the lung...
  34. doi Pathology of lung cancer
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Clin Chest Med 32:669-92. 2011
    ..Histologic criteria are also presented for other tumors...
  35. doi Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma
    Kyuichi Kadota
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York 10065, USA
    J Thorac Oncol 6:896-904. 2011
    ..We sought to investigate whether histologic subtyping can prognostically stratify patients with epithelioid DMPM...
  36. doi International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Thorac Oncol 6:244-85. 2011
    ....
  37. doi Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker
    M Catherine Pietanza
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA
    Clin Cancer Res 18:1138-45. 2012
    ..This phase II study was conducted to assess the efficacy of temozolomide in patients with relapsed small cell lung cancer (SCLC)...
  38. doi Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Semin Respir Crit Care Med 32:22-31. 2011
    ..The need for every institution to develop a multidisciplinary strategy to obtain these small specimens and process them not only for diagnosis but also for molecular testing is emphasized...
  39. doi Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas
    William D Travis
    Department of Pathology, Attending Thoracic Pathologist, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Mod Pathol 25:S18-30. 2012
    ..Brief reference will be made to other neuroendocrine lung tumors with an overview of the molecular pathogenesis of this spectrum of tumors...
  40. doi Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer
    Akihiko Yoshizawa
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 16:240-8. 2010
    ..This study explored expression of eIF4E and its relationship with the PTEN/AKT and RAS/MEK/ERK pathways in non-small cell lung carcinoma (NSCLC)...
  41. doi Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines
    Nicolas Girard
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Chest 137:46-52. 2010
    ..Here, we report on seven patients in whom epidermal growth factor receptor (EGFR) and Kirsten-rat sarcoma 2 viral oncogene homolog (KRAS) tumor mutation status was used to determine clonal relationships among multiple lung lesions...
  42. doi Ki 67 is an independent predictive biomarker of cancer specific and local recurrence-free survival after lung tumor ablation
    Constantinos T Sofocleous
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 20:S676-83. 2013
    ....
  43. pmc Primary myoepithelial carcinoma of the lung: a rare entity treated with parenchymal sparing resection
    Inderpal S Sarkaria
    Department of Surgery, Thoracic Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    J Cardiothorac Surg 6:27. 2011
    ..Although classified as low-grade neoplasms, these tumors have a significant rate of recurrence and distant metastasis...
  44. ncbi Visceral pleural invasion: pathologic criteria and use of elastic stains: proposal for the 7th edition of the TNM classification for lung cancer
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York 10021, USA
    J Thorac Oncol 3:1384-90. 2008
    ..The elastic layer of the visceral pleura is not mentioned in the current International Union Against Cancer or American Joint Committee on Cancer staging documents...